China's Structure Therapeutics soars on US debut
Structure Therapeutics, a China and US-based drug developer specialising in novel oral therapeutics, performed strongly on its trading debut following an upsized USD 161.1m NASDAQ IPO.
The company has secured USD 198m in private funding since its inception. Its backers include Sequoia Capital China, Qiming Venture Partners, Hillhouse Capital, Eight Roads Ventures, F-Prime Capital Partners,...
More on Greater China
Latest News
HKEX relaxes rules for IPOs by pre-profit tech companies
The Hong Kong Stock Exchange (HKEX) has loosened its listing requirements to allow pre-profit technology companies to go public with market capitalisations as low as HKD 6bn (USD 764m).
Asia GPs must get smarter on target selection, costs - Bain & Co
Careful target selection – based on geography and sector – and increased emphasis on cost controls during ownership will be critical factors for Asian private equity investors as the industry braces for a downturn, according to Bain & Company.
Longreach buys Japan healthcare SaaS player
North Asia buyout specialist The Longreach Group has invested an undisclosed sum in Wellness Communications Corporation (WCC), a Japanese healthcare software-as-a-service (SaaS) provider.
Asia-Europe investor AGIC supports Danish electronics buyout
AGIC Capital, a specialist in Europe-China cross-border deals, has backed the acquisition of PR Electronics, a Danish manufacturer of signal processing equipment with an existing base in China.